Angry Bear Blog
A team of six specialists, featuring a tax law expert, a historian, economists with PhDs, business consultants, and finance professionals, offers insights into the financial landscape. Although they address a wide range of economic topics, their articles delve deeply into each subject. They cover areas such as global trade, industrial output, U.S. government initiatives, and key regulatory matters.
Outlet metrics
Global
#1173440
United States
#294157
Law and Government/Government
#5473
Articles
-
Oct 22, 2024 |
angrybearblog.com | Eric Kramer
I am canvassing near Pittsburgh this week with a group of around 30. The first few days have been relatively uneventful. The weather has been beautiful. A few of my co-canvassers reported useful conversations, like one woman who wanted to vote but wasn't sure who the pro-choice candidate was. I have had one conversation with an undecided voter, a woman who spoke to me from inside her house.
-
Oct 22, 2024 |
angrybearblog.com | Bill Haskell
-
Oct 21, 2024 |
angrybearblog.com | Bill Haskell
A heads up on changes to Part D in 2025. Some you already know as a $2000 cap on Meds Part D. Premiums may increase. There is a chance for subsidies. Read on . . . Medicare, a federal health insurance program, is vital for Americans 65 and older. It is also for younger individuals with disabilities or severe illnesses. Established in 1965, it has evolved to provide essential medical coverage to millions.
-
Oct 21, 2024 |
angrybearblog.com | Bill Haskell
Recent WSJ subscription article on China and it trying to reverse its one-child per couple policy. Evidently the policy is leaving the country with a growing elderly population with no younger replacements to follow. It will now implement subsidies to encourage larger families to reverse the demographic decline of its own design. The Communist Party owns this one for a successful policy in reversing population growth.
-
Oct 21, 2024 |
angrybearblog.com | Bill Haskell
The article is talking around the issues. The country is calling on former drug company management to assist in taking down an industry giant. It probably will not succeed as many of these experts still have ties to the industry and the companies employing them. Think Azar . . . Pharma companies were using "value-based" analysis to determine old drug pricing even without improvement. This is precisely what HHS Alex Azar did at Eli Lilly with Humalog a decades old drug used to treat diabetes.
Contact details
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →